Lung Cancer Initiative
Lung cancer is the leading cause of cancer deaths globally, and it is often detected too late, with more than half of cases metastasizing by the time they are first diagnosed … but there is hope.
With patients at the heart of everything we do, The Lung Cancer Initiative (LCI) at Johnson & Johnson was formed in 2018 to unleash the full potential of lung cancer science to help change the trajectory of this complex disease.
Expand
Collapse
With patients at the heart of everything we do, The Lung Cancer Initiative (LCI) at Johnson & Johnson was formed in 2018 to unleash the full potential of lung cancer science to help change the trajectory of this complex disease.
Leadership
-
Avi Spira, M.D.,
MScGlobal Head, LCI -
Silvia Chen, Ph.D., MBA
Head of China, LCI and WWDA -
Hannah McEwen, Ph.D.
Head of Engineering Sciences, LCI -
Michael Morrissey, Ph.D.
Global Head, Early Detection & Data Science, LCI and WWDA -
Tina Soares
Vice President, LCI & WWDA Scientific & Clinical Operations -
Chris Stevenson, Ph.D.
Head of Pharmaceutical Sciences, LCI -
Philippe Szapary, M.D., MSCE
Head of Clinical Development, LCI
Featured stories & discussions
Johnson & Johnson’s integrated approach to tackling lung cancer hopes to save lives and gather lessons for other cancer types
Produced by Johnson & Johnson and Nature Research Custom Media in December 2020